Anti-CD123 chimeric antigen receptor T cell therapy (Yake Biotechnology)

N/A

Report date: 2024/05/15 16:09:09

Base Information

Drug NameAnti-CD123 chimeric antigen receptor T cell therapy (Yake Biotechnology)

Drug Alias NameCD123 CART cell therapy (Yake Biotechnology)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD123

TargetsInterleukin-3 receptor subunit alpha

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesShanghai YaKe Biotechnology Co Ltd

China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co Ltd

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A